EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Mitochondrial “swap” in the Tumor Microenvironment
Professor, Okayama University
Yosuke Togashi MD PhD is a Professor at Okayama University specializing in tumor microenvironment research He trained in respiratory medicine earned his PhD in genome biology and began cancer immunology research in
Articles
Transforming Customer Engagement in Life Sciences Adopting Hybrid Commercial Models (HCMs)
The convergence of traditional and digital channels in the life sciences industry presents significant challenges in delivering a comprehensive Customer Experience CX across all touchpoints Before Healthcare Professionals HCPs primarily engaged with life science enterprises through traditional means such as facetoface meetings
Research Insights
Determining The Frequency Of Pathogenic Germline Variants From Exome Sequencing In Patients With Castrate-resistant Prostate Cancer
Abstract Objectives To determine the frequency of pathogenic inherited mutations in select genes from patients with metastatic castrateresistant prostate cancer mCRPC Design Observational Setting Multis
Case Studies
Heat Stable Insulin Analogues (Zinc-complexed and Zinc-free)
Challenge Insulin is used to treat various forms of diabetes mellitus Patients with type I diabetes mellitus depend on external insulin most commonly injected subcutaneously for their survival because of the deficiency of the hormone Insulin is typically deli
Techno Trends
Loma Linda University Health Developed First-of-its-kind Gene Therapy for Hemophilia
Loma Linda University Health has achieved a groundbreaking milestone with the development of a pioneering gene therapy for hemophilia B complemented by dirloctocogene samoparvovec an advanced
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Is Convex Dose Dependence A Side Effect That Multiple Drug Treatment Causes?
Y-h. Taguchi obtained Dr. Sci. of Physics from Tokyo Institute of Technology. He has published papers in major journals, including Scientific Reports and PLoS ONE,a monograph from Springer International and is serving as academic editors in journals including PLoS ONE, BMC Medical Genomics and Frontiers in Genetics:RNA.
TurkiTurki received a PhD in computer science from the New Jersey Institute of Technology. He has published papers in journals, including Expert Systems with Applications, Knowledge-Based Systems, and PLoS ONE. Dr. Turki is an editorial board member of Computers in Biology and Medicine and Sustainable Computing: Informatics and Systems.
Are We Ready to Ship Billions of COVID Vaccines Worldwide?
President, Asia Pacific, Middle East and Africa, FedEx Express
The Past, Present, and Future of Sickle-cell Disease Registries: Findings from a Global Review
Sam is an Associate Director in Patient-Centered Research at Vitaccess, providing direction and oversight across their health economics and outcomes research, patient-centered outcomes, and real-world evidence portfolio. Sam joined Vitaccess in 2018, after spending three years as a project manager within the PCO group at a leading contract research organisation.
Fatemeh is a Medical Writer at Vitaccess. She plays a key role in their digital real-world evidence studies, developing materials that range from client-facing deliverables through to content communicating the value and progress of studies to clinical experts, patient representatives, and participants.
Oktawia is a Research Associate at Vitaccess, contributing to their patient-reported outcomes and clinical outcome assessment projects and supporting the development, effective delivery, and quality of their real-world studies. Oktawia has experience in health research from previous roles involving healthcare technologies, a medical ventures accelerator, and her doctoral research studies.
Akosua is an Associate Consultant at Vitaccess, currently project managing a range of their longitudinal and cross-sectional real-world evidence studies. She has experience in developing evidence-generation strategies for clients, including gap analyses for health technology assessment submissions and the reimbursement of digital health technologies.
Navigating Regulatory Frameworks: “Generic Approvals in Latin America’s Two Giants- Brazil & Mexico
Sundaraneedi Bhavya Sridevi is a Master’s student of Regulatory Affairs at National Institute of Pharmaceutical Education and Research (NIPER- Raebareli). She had a six-month internship experience at Hetero Labs in Regulatory affairs of Latin America. Her interests include global regulatory affairs and Latin American emerging market regulations.
Dr. Rahul Shukla, Assistant Professor at the Department of Pharmaceutics, NIPER Raebareli, Lucknow, an Institute of National Importance, under the Ministry of Chemicals & Fertilizers, Govt. of India. He was awarded SERB International Research Experience (SIRE) Fellow. Listed in Stanford University's Top 2% Scientists in Pharmaceutical Sciences Worldwide.
Research Interest: Pharmaceutics, Nanomedicine, Particle Engineering, Bionanomaterials for various therapeutic applications.
Analysis of Blood Microbiota Compositionin Cardiovascular Disease Patients
Dr. Ikram Khan, the first author of the Article, Studying Medical Microbiology in Lanzhou University China as a PhD student, and working on blood microbial Ecology and their association with cardiovascular disease. In March 2022, we published two Articles on this work. Email: ikram2018@lzu.edu.cn
Assistant Professor Imran Khan, 2nd Author of this article, Supervises BS(Hons) students and is engaged in the teaching and research of Bacteriology, Nano-medicine, and Molecular Biology. Presently working as, a member of Quality Enhancement Cell at Xcito School of Nursing and Allied Health Sciences Pakistan. Email:Imran.mic727@gmail.com
Professor Zhou Jianye, is also Co-supervisor of this study, and supervises Master students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology at School of Northwest Minzu University”.Email: 14092785@qq.com
Professor Xie Ping, supervises Master and PhD students.She has long been engaged in the research of cardiovascular disease pathogenesis and drug prevention. Her current status is “Director of Cardiovascular Center of Gansu Provincial Hospital”.
Professor Li Zhiqiang, is a Co-supervisor of this study, and supervises Master and PhD students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology. His current status is “Director of graduate School of Northwest Minzu University”. Email: Lizhiqiang6767@163.com
Professor An Lizhe, supervise this work as a First Supervisor. He supervises PhD and doctoral students, and engaged in the Teaching and Research of Molecular Biology, Environmental Botany and Ecology. Currently working as, a President and Deputy Secretary of the Party Committee of Beijing Forestry University. Email: yxlzq@xbmu.edu.cn
Dr. Zhang Xiaowei is a professor, chief physician, director of the second ward of cardiovascular medicine, and deputy director of the Science and Technology Department. He has completed projects such as epidemiological investigation and prevention plan research of hypertension in Gansu Province and has published many SCI and CSCD papers, and currently undertakes 1st national natural science foundation, 2nd provincial natural science foundations, and 1st municipal science foundation.
press releasesRead more...
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy
HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases
HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation
Cotecna Group Acquires Energon Labs
Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
EventsRead more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...